First AD

Second AD

Patrick Y. Wen, MD, is is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the safety profile and management of toxicities associated with BRAF inhibitors in central nervous system tumors.

Safety Considerations for BRAF Inhibition in CNS Malignancies

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.
